<p>Drucker Wealth 3.0 LLC 在最近向证券交易委员会的披露中表示，在第二季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的持股减少了 34.5%。该基金在季度内出售了 1,307 股后，持有该公司 2,484 股股票。Drucker Wealth 3.0 LLC 在 Cencora 的持股在最近的报告期末价值为 746,000 美元。</p>
<ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
<p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Cornerstone Planning Group LLC 在第一季度将其在 Cencora 的持股增加了 106.7%。Cornerstone Planning Group LLC 目前持有 93 股该公司的股票，价值 26,000 美元，此前在上个季度又购买了 48 股。Hoey Investments Inc. 在第一季度获得了 Cencora 的新头寸，估值约为 28,000 美元。Costello Asset Management INC 在第一季度获得了 Cencora 的新头寸，估值约为 28,000 美元。德克萨斯大学德克萨斯农工投资管理公司在第一季度获得了 Cencora 的新头寸，估值约为 39,000 美元。最后，Golden State Wealth Management LLC 在第一季度将其在 Cencora 的持股增加了 157.6%。Golden State Wealth Management LLC 目前持有 170 股该公司的股票，价值 47,000 美元，此前在上个季度又购买了 104 股。97.52% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>Cencora 价格表现</h2>
<p>Cencora 股票在周五开盘价为 318.01 美元。该公司的市值为 616.6 亿美元，市盈率为 32.72，市盈增长比率为 1.47，贝塔值为 0.63。该公司的速动比率为 0.53，流动比率为 0.90，债务股本比率为 3.64。Cencora, Inc. 的 52 周低点为 221.95 美元，52 周高点为 319.68 美元。该公司的 50 日移动平均线为 296.99 美元，200 日移动平均线为 291.60 美元。</p>
<ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
<p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近在 8 月 6 日星期三公布了季度财报。该公司报告每股收益（EPS）为 4.00 美元，超出市场共识预期的 3.79 美元，超出 0.21 美元。该公司在本季度的收入为 806.6 亿美元，而分析师预期为 803.4 亿美元。Cencora 的股本回报率为 267.36%，净利润率为 0.60%。该公司的季度收入同比增长 8.7%。去年同期，该公司每股收益为 3.34 美元。研究分析师平均预计 Cencora, Inc. 本财年将发布 15.37 美元的每股收益。</p>
<h2>Cencora 宣布分红</h2>
<p>该公司最近还披露了季度分红，已于 9 月 3 日星期三支付。8 月 15 日星期五的股东获得了 0.55 美元的分红。这相当于年化 2.20 美元的分红和 0.7% 的分红收益率。除息日为 8 月 15 日星期五。Cencora 的分红支付比率（DPR）目前为 22.63%。</p>
<h2>内部人士下注</h2>
<ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
<p>在其他新闻中，首席执行官 Robert P. Mauch 于 9 月 18 日星期四出售了 5,097 股公司的股票，交易价格为每股 290.00 美元，总价值为 1,478,130.00 美元。出售后，首席执行官直接持有该公司 39,274 股，价值约为 11,389,460 美元。这笔交易代表其持股减少了 11.49%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，董事长 Steven H. Collis 于 9 月 16 日星期二出售了 31,350 股公司的股票，交易价格为每股 289.86 美元，总价值为 9,087,111.00 美元。完成出售后，董事长持有该公司 305,913 股，价值约为 88,671,942.18 美元。这代表其持股减少了 9.30%。该交易的披露可以在这里找到。过去 90 天内，内部人士共出售了价值 16,292,923 美元的 55,993 股公司股票。公司内部人士持有该公司 10.80% 的股票。</p>
<h2>分析师评级上调和下调</h2>
<p>一些研究分析师最近对该公司进行了评论。摩根士丹利在 7 月 16 日的报告中对 Cencora 设定了 330.00 美元的目标价，并给予公司 “持平” 评级。富国银行将 Cencora 的目标价从 337.00 美元上调至 354.00 美元，并在 8 月 13 日的研究报告中给予公司 “增持” 评级。华尔街 Zen 将 Cencora 的评级从 “买入” 下调至 “持有”。Evercore ISI 在一份研究报告中对 Cencora 的目标价设定为 340.00 美元。最后，Jefferies Financial Group 将 Cencora 的目标价从 275.00 美元上调至 300.00 美元，并在 6 月 30 日的报告中给予该股票 “持有” 评级。九位研究分析师对该股票给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat，Cencora 目前的平均评级为 “适度买入”，平均目标价为 320.00 美元。</p>
<p><strong>查看我们对 Cencora 的最新股票分析</strong></p>
<h2>Cencora 公司简介</h2>
<p>（免费报告）</p>
<p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立及连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配置和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>3 只 heavily shorted 股票可能在降息时反弹</li>
<li>CD 计算器：定期存款计算器</li>
<li>博通获得第二个 420 美元目标，CPO 胜利提升前景</li>
<li>这些液化天然气股票准备迎来上涨反弹吗？</li>
<li>百事可乐的深度折扣即将消失：趁现在买入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Drucker Wealth 3.0 LLC 在第二季度减少了对 Cencora, Inc. (NYSE:COR) 的持股比例，下降了 34.5%，目前持有 2,484 股，价值 746,000 美元。其他机构投资者也调整了他们的持仓。Cencora 的股票开盘价为 318.01 美元，市值为 616.6 亿美元，市盈率为 32.72。该公司报告第二季度每股收益为 4.00 美元，超出预期，并宣布季度股息为 0.55 美元。在过去 90 天内，内部人士总共出售了 55,993 股，价值 1,629 万美元，内部人士持有该公司 10.80% 的股份</p>

<p>Drucker Wealth 3.0 LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 34.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,484 shares of the company's stock after selling 1,307 shares during the quarter. Drucker Wealth 3.0 LLC's holdings in Cencora were worth $746,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Drucker Wealth 3.0 LLC 在最近向证券交易委员会的披露中表示，在第二季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的持股减少了 34.5%。该基金在季度内出售了 1,307 股后，持有该公司 2,484 股股票。Drucker Wealth 3.0 LLC 在 Cencora 的持股在最近的报告期末价值为 746,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cornerstone Planning Group LLC boosted its stake in Cencora by 106.7% during the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock worth $26,000 after buying an additional 48 shares during the last quarter. Hoey Investments Inc. acquired a new position in Cencora in the 1st quarter valued at about $28,000. Costello Asset Management INC acquired a new position in Cencora in the 1st quarter valued at about $28,000. University of Texas Texas AM Investment Management Co. acquired a new position in Cencora in the 1st quarter valued at about $39,000. Finally, Golden State Wealth Management LLC lifted its holdings in Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after acquiring an additional 104 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Cornerstone Planning Group LLC 在第一季度将其在 Cencora 的持股增加了 106.7%。Cornerstone Planning Group LLC 目前持有 93 股该公司的股票，价值 26,000 美元，此前在上个季度又购买了 48 股。Hoey Investments Inc. 在第一季度获得了 Cencora 的新头寸，估值约为 28,000 美元。Costello Asset Management INC 在第一季度获得了 Cencora 的新头寸，估值约为 28,000 美元。德克萨斯大学德克萨斯农工投资管理公司在第一季度获得了 Cencora 的新头寸，估值约为 39,000 美元。最后，Golden State Wealth Management LLC 在第一季度将其在 Cencora 的持股增加了 157.6%。Golden State Wealth Management LLC 目前持有 170 股该公司的股票，价值 47,000 美元，此前在上个季度又购买了 104 股。97.52% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Cencora Price Performance</h2>
<div class="lb-trans"><h2>Cencora 价格表现</h2>
</div><p>Cencora stock opened at $318.01 on Friday. The firm has a market cap of $61.66 billion, a PE ratio of 32.72, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 52-week low of $221.95 and a 52-week high of $319.68. The company's 50 day moving average is $296.99 and its two-hundred day moving average is $291.60.</p>
<div class="lb-trans"><p>Cencora 股票在周五开盘价为 318.01 美元。该公司的市值为 616.6 亿美元，市盈率为 32.72，市盈增长比率为 1.47，贝塔值为 0.63。该公司的速动比率为 0.53，流动比率为 0.90，债务股本比率为 3.64。Cencora, Inc. 的 52 周低点为 221.95 美元，52 周高点为 319.68 美元。该公司的 50 日移动平均线为 296.99 美元，200 日移动平均线为 291.60 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
</div><p>Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to analysts' expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the firm earned $3.34 earnings per share. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近在 8 月 6 日星期三公布了季度财报。该公司报告每股收益（EPS）为 4.00 美元，超出市场共识预期的 3.79 美元，超出 0.21 美元。该公司在本季度的收入为 806.6 亿美元，而分析师预期为 803.4 亿美元。Cencora 的股本回报率为 267.36%，净利润率为 0.60%。该公司的季度收入同比增长 8.7%。去年同期，该公司每股收益为 3.34 美元。研究分析师平均预计 Cencora, Inc. 本财年将发布 15.37 美元的每股收益。</p>
</div><h2>Cencora Announces Dividend</h2>
<div class="lb-trans"><h2>Cencora 宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora's dividend payout ratio (DPR) is presently 22.63%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 9 月 3 日星期三支付。8 月 15 日星期五的股东获得了 0.55 美元的分红。这相当于年化 2.20 美元的分红和 0.7% 的分红收益率。除息日为 8 月 15 日星期五。Cencora 的分红支付比率（DPR）目前为 22.63%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
</div><p>In other news, CEO Robert P. Mauch sold 5,097 shares of the firm's stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the sale, the chief executive officer directly owned 39,274 shares in the company, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,993 shares of company stock worth $16,292,923 over the last 90 days. Company insiders own 10.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Robert P. Mauch 于 9 月 18 日星期四出售了 5,097 股公司的股票，交易价格为每股 290.00 美元，总价值为 1,478,130.00 美元。出售后，首席执行官直接持有该公司 39,274 股，价值约为 11,389,460 美元。这笔交易代表其持股减少了 11.49%。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，董事长 Steven H. Collis 于 9 月 16 日星期二出售了 31,350 股公司的股票，交易价格为每股 289.86 美元，总价值为 9,087,111.00 美元。完成出售后，董事长持有该公司 305,913 股，价值约为 88,671,942.18 美元。这代表其持股减少了 9.30%。该交易的披露可以在这里找到。过去 90 天内，内部人士共出售了价值 16,292,923 美元的 55,993 股公司股票。公司内部人士持有该公司 10.80% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>A number of research analysts recently commented on the company. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, July 16th. Wells Fargo &amp; Company upped their price target on Cencora from $337.00 to $354.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, August 13th. Wall Street Zen lowered Cencora from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Evercore ISI set a $340.00 target price on shares of Cencora in a research report on Wednesday. Finally, Jefferies Financial Group upped their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a &#34;hold&#34; rating in a report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Cencora currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $320.00.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司进行了评论。摩根士丹利在 7 月 16 日的报告中对 Cencora 设定了 330.00 美元的目标价，并给予公司 “持平” 评级。富国银行将 Cencora 的目标价从 337.00 美元上调至 354.00 美元，并在 8 月 13 日的研究报告中给予公司 “增持” 评级。华尔街 Zen 将 Cencora 的评级从 “买入” 下调至 “持有”。Evercore ISI 在一份研究报告中对 Cencora 的目标价设定为 340.00 美元。最后，Jefferies Financial Group 将 Cencora 的目标价从 275.00 美元上调至 300.00 美元，并在 6 月 30 日的报告中给予该股票 “持有” 评级。九位研究分析师对该股票给予了买入评级，三位分析师给予了持有评级。根据 MarketBeat，Cencora 目前的平均评级为 “适度买入”，平均目标价为 320.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Cencora 的最新股票分析</strong></p>
</div><h2>Cencora Company Profile</h2>
<div class="lb-trans"><h2>Cencora 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc. 负责药品的采购和分销。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立及连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配置和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品上市后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>3 Heavily Shorted Stocks That Could Pop on Rate Cuts</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Broadcom Gets Second $420 Target as CPO Win Boosts Outlook</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>3 只 heavily shorted 股票可能在降息时反弹</li>
<li>CD 计算器：定期存款计算器</li>
<li>博通获得第二个 420 美元目标，CPO 胜利提升前景</li>
<li>这些液化天然气股票准备迎来上涨反弹吗？</li>
<li>百事可乐的深度折扣即将消失：趁现在买入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Drucker Wealth 3.0 LLC 出售了 Cencora, Inc. 的 $COR 股票